Derek Maetzold Sells 859 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 859 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $20.00, for a total transaction of $17,180.00. Following the completion of the transaction, the insider directly owned 2,158 shares of the company’s stock, valued at approximately $43,160. The trade was a 28.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Down 1.9%

CSTL stock traded down $0.39 during trading on Friday, reaching $20.15. The company had a trading volume of 289,270 shares, compared to its average volume of 406,556. Castle Biosciences, Inc. has a 52 week low of $14.59 and a 52 week high of $44.28. The company has a market cap of $611.15 million, a P/E ratio of -45.80 and a beta of 1.11. The business has a 50 day moving average of $23.57 and a 200 day moving average of $31.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. The company had revenue of $84.23 million during the quarter, compared to the consensus estimate of $79.23 million. As a group, sell-side analysts forecast that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of CSTL. Amundi grew its holdings in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after purchasing an additional 4,111 shares during the period. AQR Capital Management LLC grew its holdings in shares of Castle Biosciences by 548.9% during the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after buying an additional 115,907 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after buying an additional 655 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Castle Biosciences by 34.7% during the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock valued at $713,000 after buying an additional 8,992 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

CSTL has been the subject of a number of research reports. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th. Guggenheim upped their price objective on shares of Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wall Street Zen cut shares of Castle Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Finally, Canaccord Genuity Group cut their price objective on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $45.33.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.